Your browser doesn't support javascript.
loading
Development of a Curcumin-Loaded Lecithin/Chitosan Nanoparticle Utilizing a Box-Behnken Design of Experiment: Formulation Design and Influence of Process Parameters.
Walbi, Ismail A; Ahmad, Mohammad Zaki; Ahmad, Javed; Algahtani, Mohammed S; Alali, Amer S; Alsudir, Samar A; Aodah, Alhassan H; Albarqi, Hassan A.
Afiliación
  • Walbi IA; Department of Clinical Pharmacy, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.
  • Ahmad MZ; Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.
  • Ahmad J; Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.
  • Algahtani MS; Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.
  • Alali AS; Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kkharj 11942, Saudi Arabia.
  • Alsudir SA; National Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.
  • Aodah AH; National Center of Biotechnology, Life Science and Environment Research Institute, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.
  • Albarqi HA; Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 11001, Saudi Arabia.
Polymers (Basel) ; 14(18)2022 Sep 08.
Article en En | MEDLINE | ID: mdl-36145903
ABSTRACT
Curcumin (CUR) has impressive pharmacologic properties, including cardioprotective, neuroprotective, antimicrobial, and anticancer activity. However, the pharmaceutical application of CUR is limited due to its poor aqueous solubility and low bioavailability. The development of novel formulations has attracted considerable attention to the idea of applying nanobiotechnology to improve the therapeutic efficacy of these challenging compounds. In this study, CUR-loaded lecithinchitosan nanoparticles (CUR/LCSNPs) were developed and optimized by the concentration of chitosan, lecithin, and stirring speed by a 3-factorial Box-Behnken statistical design, resulting in an optimal concentration of chitosan (A) and lecithin (B) with a 1200 rpm stirring speed (C), with applied constraints of minimal average particle size (Y1), optimal zeta potential (Y2), and maximum entrapment efficiency (%EE) (Y3). The mean particle size of the checkpoint formulation ranged from 136.44 ± 1.74 nm to 267.94 ± 3.72, with a zeta potential of 18.5 ± 1.39 mV to 36.8 ± 3.24 mV and %EE of 69.84 ± 1.51% to 78.50 ± 2.11%. The mean particle size, zeta potential, %EE, and % cumulative drug release from the optimized formulation were 138.43 ± 2.09 nm, +18.98 ± 0.72 mV, 77.39 ± 1.70%, and 86.18 ± 1.5%, respectively. In vitro drug release followed the Korsmeyer−Peppas model with Fickian diffusion (n < 0.45). The optimized technique has proven successful, resulting in a nanoformulation that can be used for the high loading and controlled release of lipophilic drugs.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Polymers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Arabia Saudita

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Polymers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Arabia Saudita